|Name||PRICE||MARKET CAPITALIZATION||PRICE TO EARNINGS RATIO||DIVIDEND YIELD||SYMBOL||EXCHANGE||PRICE PERCENT DIFFERENCE||YEAR TO DATE PRICE PERCENT DIFFERENCE||5 YEAR CHART||1 YEAR CHART|
Madrigal Pharmaceuticals Inc [MDGL]
$98.46 1.32 (1.32%)
Market Cap 1.54 Billion
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed ÃƒÂŸ-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. In addition, MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action. Geographically, all the business activity is functioned through the US.
EPS -0.98 P/E Ratio 0.00
Previous Earnings Wed, Feb 27, 2019
Pay Date --